+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission



Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission



Hepatology International 4(4): 757-761



Bioartificial liver assist devices (BLADs) are expected to bridge liver failure patients to liver transplantation, but porcine endogenous retroviruses (PERVs) still pose a potential risk in pig-to-human xenotransplantation and thereby limit the use of bioartificial liver therapy. In our lab, fluidized-bed BLADs based on microencapsulated primary porcine hepatocytes have been successfully used to treat liver failure pigs. We detected the risk of PERVs transmission of microencapsulated primary porcine hepatocytes-the key component of fluidized-bed BLADs, to evaluate the biosafety of this device for further clinical applications. Microencapsulated primary porcine hepatocytes (cell diameter = 300 μm) were cultured in Dulbecco's modified Eagles medium (DMEM). Microencapsulated cell culture supernatants were collected at 6, 12, 24 and 72 h. HEK-293 were cocultured with these supernatants, and the cocultured cells were harvested every 7 days. RT-PCR was used to detect PERVs transmission. RT-qPCR was used to get the number of virus copies. PK-15 was used as the positive control whereas HepG2 was used as the negative control. PERV was detected in all supernatants, and the viral load of the supernatants increased with time. Moreover, cocultured 293 cells were positive for PERV-specific sequences. The kind of fluidized-bed BLADs based on microencapsulated primary porcine hepatocytes have risk of PERVs transmission. Further extensive pre-clinical study focused on biosafety is warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053265317

Download citation: RISBibTeXText

PMID: 21286347

DOI: 10.1007/s12072-010-9210-6


Related references

No transmission of porcine endogenous retrovirus in an acute liver failure model treated by a novel hybrid bioartificial liver containing porcine hepatocytes. Hepatobiliary and Pancreatic Diseases International 14(5): 492-501, 2015

No transmission of porcine endogenous retrovirus in an acute liver failure model treated by a novel hybrid bioartificial liver containing porcine hepatocytes. Hepatobiliary & Pancreatic Diseases International 14(5): 492-501, 2015

A new retrospective study on transmission of porcine endogenous retroviruses in patients treated with a bioreactor based on porcine liver cells. Xenotransplantation 10(5): 496, 2003

Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation 73(3): 420-429, 2002

Risk of porcine endogenous retrovirus infection caused by different bioartificial liver devices. International Journal of Artificial Organs 23(8): 565, 2000

Effects of anticoagulants on porcine hepatocytes in vitro: implications in the porcine hepatocyte-based bioartificial liver. International Journal of Artificial Organs 22(5): 329-333, 1999

Effects of Anticoagulants on Porcine Hepatocytes in Vitro: Implications in the Porcine Hepatocyte-Based Bioartificial Liver. The International Journal of Artificial Organs 22(5): 329-333, 1999

Absence of porcine endogenous retrovirus infection after treatment with a porcine-based bioartificial liver. Hepatology 28(4 Part 2): 495A, 1998

Primary porcine hepatocytes cultured in serum-free chemically-defined media formulations retain significant liver-specific functional parameters suitable for bioartificial liver devices. Hepatology 32(4 Pt 2): 400A, 2000

Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. Journal of Clinical Virology 28(2): 141-154, 2003

Evaluation of extracorporeal porcine liver perfusion and bioartificial liver as liver assist devices. Hepatology 30(4 Part 2): 164A, 1999

Lack of pig endogenous retroviruses transmission in a patient exposed to porcine hepatocytes in vivo. Cell Transplantation 8(2): 177, March-April, 1999

Long-term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cell-based Academic Medical Center bioartificial liver. Xenotransplantation 17(6): 431-439, 2011

Porcine hepatocytes from slaughterhouse organs. An unlimited resource for bioartificial liver devices. Asaio Journal 41(2): 189-193, 1995

Increased survival in fulminant hepatic failure rats following treatment with the UCLA bioartificial liver support device that utilizes microencapsulated porcine hepatocytes. Gastroenterology 110(4 Suppl. ): A1182, 1996